Literature DB >> 25028377

Work productivity loss and fatigue in psoriatic arthritis.

Jessica A Walsh1, Molly L McFadden2, Michael D Morgan2, Allen D Sawitzke2, Kristina Callis Duffin2, Gerald G Krueger2, Daniel O Clegg2.   

Abstract

OBJECTIVE: To explore the relationship between fatigue and work productivity loss (WPL) in people with psoriatic arthritis (PsA).
METHODS: Data were collected from participants in the Utah Psoriasis Initiative Arthritis registry between January 2010 and May 2013. WPL was measured with the 8-item Work Limitations Questionnaire. Fatigue was assessed with question 1 from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI#1), "How would you describe the overall level of fatigue/tiredness you have experienced?" and with question 1 from the Psoriatic Arthritis Quality of Life Questionnaire (PsAQOL#1) "I feel tired whatever I do." Psoriatic activity was evaluated with tender joint count (TJC), swollen joint count (SJC), dactylitis count, enthesitis count, inflammatory back pain (IBP), physician global assessment, body surface area, and psoriasis pain and itch.
RESULTS: Among 107 participants, work productivity was reduced by 6.7%, compared to benchmark employees without limitations. Fatigue was reported by 54 patients (50.5%) on PsAQOL#1, and 64 (60.0%) were classified as high fatigue by BASDAI#1. TJC, SJC, enthesitis count, IBP, and depressed mood were highest or most frequent in participants reporting fatigue. After adjustments for psoriatic activity and depressed mood, WPL was associated with fatigue, as measured by PsAQOL#1 (p = 0.01) and BASDAI#1 (p = 0.002).
CONCLUSION: WPL was associated with fatigue, and the association was not entirely explained by the evaluated musculoskeletal, cutaneous, or psychiatric manifestations of PsA.

Entities:  

Keywords:  DISABILITY; FATIGUE; PSORIATIC ARTHRITIS; QUALITY OF LIFE; WORK

Mesh:

Year:  2014        PMID: 25028377     DOI: 10.3899/jrheum.140259

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study.

Authors:  Rieke Alten; P G Conaghan; V Strand; E Sullivan; S Blackburn; H Tian; K Gandhi; S M Jugl; A Deodhar
Journal:  Clin Rheumatol       Date:  2019-02-04       Impact factor: 2.980

2.  Systematic review of mental health comorbidities in psoriatic arthritis.

Authors:  Sizheng Steven Zhao; Natasha Miller; Nicholas Harrison; Stephen J Duffield; Mrinalini Dey; Nicola J Goodson
Journal:  Clin Rheumatol       Date:  2019-09-05       Impact factor: 2.980

Review 3.  Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.

Authors:  Patompong Ungprasert; Charat Thongprayoon; John M Davis
Journal:  Clin Rheumatol       Date:  2016-02-06       Impact factor: 2.980

4.  Validity and Reliability of the 8-Item Work Limitations Questionnaire.

Authors:  Timothy J Walker; Jessica M Tullar; Pamela M Diamond; Harold W Kohl; Benjamin C Amick
Journal:  J Occup Rehabil       Date:  2017-12

5.  Role of Sleep Disturbance, Depression, Obesity, and Physical Inactivity in Fatigue in Rheumatoid Arthritis.

Authors:  Patricia Katz; Mary Margaretten; Laura Trupin; Gabriela Schmajuk; Jinoos Yazdany; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-01       Impact factor: 4.794

6.  Prevalence and variables associated with fatigue in psoriatic arthritis: a cross-sectional study.

Authors:  Joel Shi Quan Tan; Warren Fong; Yu Heng Kwan; Ying Ying Leung
Journal:  Rheumatol Int       Date:  2020-08-09       Impact factor: 2.631

Review 7.  Measuring Outcomes in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura C Coates; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

8.  Methotrexate for psoriatic arthritis.

Authors:  Tom D Wilsdon; Samuel L Whittle; Tilenka Rj Thynne; Arduino A Mangoni
Journal:  Cochrane Database Syst Rev       Date:  2019-01-18

9.  Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Authors:  Ana-Maria Orbai; Maarten de Wit; Philip J Mease; Kristina Callis Duffin; Musaab Elmamoun; William Tillett; Willemina Campbell; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Laure Gossec; Pil Hoejgaard; Ying Ying Leung; Chris Lindsay; Vibeke Strand; Désirée M van der Heijde; Bev Shea; Robin Christensen; Laura Coates; Lihi Eder; Neil McHugh; Umut Kalyoncu; Ingrid Steinkoenig; Alexis Ogdie
Journal:  J Rheumatol       Date:  2017-02-01       Impact factor: 4.666

10.  Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.

Authors:  Proton Rahman; Philip J Mease; Philip S Helliwell; Atul Deodhar; Laure Gossec; Arthur Kavanaugh; Alexa P Kollmeier; Elizabeth C Hsia; Bei Zhou; Xiwu Lin; May Shawi; Chetan S Karyekar; Chenglong Han
Journal:  Arthritis Res Ther       Date:  2021-07-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.